What Is Vitamin D3?
Vitamin D3 (cholecalciferol) is a fat-soluble vitamin and prohormone. In the body it is first converted in the liver to 25-OH-D3 (calcidiol), then in the kidneys to the active form calcitriol (1,25-dihydroxyvitamin D). Calcitriol acts as a steroid hormone at vitamin D receptors found in almost all body tissues — bone, muscle, immune cells, heart, brain, and gut are all involved.
Approximately 80% of the body’s requirement is met through UVB irradiation of the skin. In northern and central Europe, meaningful endogenous synthesis is only possible from roughly May to September around midday. During winter months, sunlight is insufficient and levels in most people decline significantly.
How Common Is Deficiency?
Data from health surveys across northern and central Europe indicate that a significant proportion of the population — estimates range from 40–60% — have 25-OH-D3 levels below 50 nmol/L in winter, the threshold defined by most national guidelines as sufficient. High-risk groups include:
- Adults aged 65+ (lower skin synthesis, less time outdoors)
- People with darker skin pigmentation (higher melanin reduces UVB absorption)
- People with obesity (vitamin D is sequestered in adipose tissue)
- Those with little sun exposure, care home residents
- People with malabsorption disorders (Crohn’s disease, coeliac disease, gastric bypass)
What Do the Studies Show?
Clearly established
Bone and fractures: Vitamin D is essential for intestinal calcium absorption. A pooled analysis of 11 RCTs (Bischoff-Ferrari et al. 2012, n=31,022) showed: vitamin D at least 800 IU/day reduced hip fractures in people aged 65+ by ~30% vs. placebo — but only in combination with adequate calcium intake.
Respiratory infections: The Cochrane meta-analysis by Martineau et al. (2017, n=11,321) showed moderate protection against acute respiratory infections (aOR 0.88; 95% CI 0.81–0.96). Effect was strongest in people with severe baseline deficiency (levels below 25 nmol/L).
Muscle strength and fall prevention: Multiple meta-analyses show a ~10–20% reduction in falls in people aged 65+ with daily supplementation of at least 800 IU. This is one of the most consistent effects in vitamin D research.
Mortality: A meta-analysis of 18 RCTs (Autier & Gandini 2007, n=57,311) showed a 7% reduction in all-cause mortality (RR 0.93; 95% CI 0.87–0.99) — effects mainly in deficient populations.
Less certain
Cardiovascular disease and cancer: The VITAL trial (Manson 2019, n=25,871) — one of the largest vitamin D trials ever conducted — found no significant benefit from 2,000 IU/day for cardiovascular events or cancer incidence in primary prevention in adequately nourished individuals.
Depression and cognition: Observational studies show associations, but RCTs are inconsistent. No established benefit in people without deficiency.
Dosage and Supplementation
| Situation | Recommendation | Notes |
|---|---|---|
| Prevention / maintenance in winter | 1,000–2,000 IU/day (25–50 µg) | If sun exposure is limited |
| Correcting deficiency | 2,000–4,000 IU/day | Adjust based on blood levels |
| EU Reference Intake | 600–800 IU/day (15–20 µg) | Without adequate sun exposure |
| EFSA Upper Level | 4,000 IU/day | Long-term safety limit for adults |
Vitamin D is fat-soluble — taking it with a meal improves absorption by ~30%. Toxicity (hypercalcaemia) occurs only with sustained intake above 10,000 IU/day; at usual supplement doses, this is not a realistic concern.
Combination with K2: Often recommended to direct calcium into bone rather than vessel walls. Direct RCT evidence for this combination in healthy individuals is limited; the safety profile is good. For severe vitamin D deficiency, K2 is not a strict requirement.
Testing: When Is It Worth It?
Diagnosis via the 25-OH-D3 serum test (target ≥50 nmol/L per most guidelines, some clinicians use ≥75 nmol/L). If you belong to a high-risk group, testing at least once is worthwhile.
Research Limitations
- Many older studies used doses too low (400 IU/day) to be informative
- Short durations (under 1 year) miss cumulative bone effects
- Confounding: healthier, more active people have higher vitamin D levels through lifestyle, not supplements
- Large RCTs like VITAL enrolled people with adequate baseline levels — results don’t directly apply to deficient populations
- Dose-response is non-linear: benefit rises more steeply below 50 nmol/L and flattens above
EFSA Status
EFSA has approved multiple health claims for vitamin D. Approved statements include:
- Contributes to normal absorption of calcium and phosphorus, and normal bone and teeth
- Normal muscle function
- Normal immune system function
- Reduction of the risk of falling in people aged 60+ (daily dose of at least 20 µg)
These claims apply to products providing at least 15% of the NRV (= 1.5 µg / 60 IU) per stated daily serving.
Summary
Vitamin D3 is not a magic bullet, but in confirmed deficiency — which is widespread in winter in northern and central Europe — it is relevant and well studied. For bone health, muscle strength, and infection prevention in at-risk groups, the evidence is strong. As a general longevity supplement for adequately nourished individuals, the established additional benefit is considerably weaker.